Spore.Bio Raises $23M to Revolutionize Microbiology Testing
- Spore.Bio raises $23M in Series A funding
- Technology uses machine learning and spectral signatures to detect bacteria and pathogens
- Reduces testing time from days to minutes
- Already signed commercial contracts with major companies
- Waitlist of customers eager to adopt the technology
- Funding round led by Singular, with participation from Point 72 Ventures and others
Spore.Bio's technology has the potential to transform the food and beverage industry by reducing the time and cost associated with traditional microbiology testing methods. The company's founders, including CEO Amine Raji, have a strong background in the industry and have developed a pre-trained deep learning algorithm that can detect bacteria and pathogens in minutes. Spore.Bio has already signed commercial contracts with several major companies and has a waitlist of customers eager to adopt its technology. The funding round was led by Singular, with participation from Point 72 Ventures, 1st Kind Ventures, and other investors. With this investment, Spore.Bio plans to expand its team and develop new products to meet the growing demand for its technology.